CRSP CRISPR Therapeutics AG

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRSP

Price (delayed)

$60.08

Market cap

$5.79B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.2

Enterprise value

$6.15B

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 29

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that ...

Highlights
CRSP's quick ratio is up by 35% QoQ and by 15% YoY
The company's gross profit has shrunk by 89% YoY but it rose by 17% QoQ
The revenue has dropped by 89% year-on-year but it has grown by 17% since the previous quarter
The equity has decreased by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://crisprtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRSP

CRSP stock price

How has the CRISPR Therapeutics AG stock price performed over time
Intraday
8.02%
1 week
11.3%
1 month
15.49%
1 year
16.28%
YTD
14.57%
QTD
10.16%

Financial performance

How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$4.1M
Gross profit
$4.1M
Operating income
-$646.4M
Net income
-$568.53M
Gross margin
100%
Net margin
-13,856.5%
The company's gross profit has shrunk by 89% YoY but it rose by 17% QoQ
The revenue has dropped by 89% year-on-year but it has grown by 17% since the previous quarter
The company's net income fell by 47% YoY but it rose by 2.2% QoQ
The company's operating income fell by 36% YoY but it rose by 2.7% QoQ

Price vs fundamentals

How does CRSP's price correlate with its fundamentals

Growth

What is CRISPR Therapeutics AG's growth rate over time

Valuation

What is CRISPR Therapeutics AG stock price valuation
CRSP P/E details
P/E
N/A
P/B
3.18
P/S
1,406.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,499.23
The EPS has declined by 38% year-on-year but it is up by 4.2% since the previous quarter
The price to book (P/B) is 38% higher than the 5-year quarterly average of 2.3 and 18% higher than the last 4 quarters average of 2.7
The equity has decreased by 6% QoQ
The price to sales (P/S) is 107% higher than the last 4 quarters average of 680.7
The revenue has dropped by 89% year-on-year but it has grown by 17% since the previous quarter

Efficiency

How efficient is CRISPR Therapeutics AG business performance
The ROE has plunged by 54% YoY
The company's return on assets fell by 43% YoY but it rose by 8% QoQ
The ROIC fell by 37% YoY but it rose by 12% QoQ
The return on sales is up by 16% since the previous quarter

Dividends

What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRSP.

Financial health

How did CRISPR Therapeutics AG financials performed over time
CRISPR Therapeutics AG's total assets is 199% more than its total liabilities
The total liabilities has surged by 170% year-on-year and by 165% since the previous quarter
CRISPR Therapeutics AG's current ratio has increased by 35% from the previous quarter and by 15% YoY
The debt is 57% smaller than the equity
The equity has decreased by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.